On January 21, 2020, the CDC reported the detection of the first person in the United States diagnosed with 2019-nCoV infection. The case history of this 35-year-old male, who became known as patient zero, was published, and said to have returned to Washington state from Wuhan, China on 15th January. [4, 5, 6] The CDC press release added, “While originally thought to be spreading from animal-to-person, there are growing indications that limited person-to-person spread is happening. It’s unclear how easily this virus is spreading between people.” [3] Genome testing, confirmed by Kristian Andersen, connected "patient zero" with the Life Care Center nursing home in Kirkland, Washington, where nearly half of initial COVID-19 deaths occurred. The patented drug remdesivir by Gilead and which was "not yet licensed or approved anywhere globally", was administered intravenously on day 7 of illness this first patient, by 30 January the patients symptoms had resolved, except for a mild cough. The patient was treated with antibiotics on day 6 when pneumonia began to develop! [5] Recovery was "attributed" to remdesivir, but the virus began to clear on day 3 (PCR Ct confirmed), and antibiotics cleared the lung infection! A few days later China began testing remdesivir..
> READ MORE